Amyloid distribution study by high spec brain-dedicated PET

Takahashi Miwako0 sites20 target enrollmentDecember 4, 2023

Overview

No summary available.

Registry

who.int

Start Date

December 4, 2023

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Takahashi Miwako

•1\. Patients who complained of subjective cognitive decline and visited a neurologist due to memory impairment and was suspected to be in the early stages of Alzheimer's disease according to the symptoms.
•2\. Age at the time of informed consent is 40 to 80 years old, regardless of gender.
•3\. Patients who had a score of 24 points or higher on MMSE conducted within 6 months before consent was obtained.
•4\. Patients who are judged by the principal investigator to be capable of understanding the study explanation and consent document.

•1\. History of hypersensitivity to alcohol.
•2\. History of serious complications, medical or surgery.
•3\. Patients currently taking medications; narcotics, psychotropic drugs, or anti\-Parkinson's drugs.
•4\. Taking medications for diabetes mellitus.
•5\. Claustrophobia.
•6\. People who have difficulty undergoing head MRI due to tattoos (including tattoos and permanent makeup), pacemakers, cochlear implants, etc.
•7\.Patients who are pregnant or may be pregnant, or who are breastfeeding.
•8\.Patient who is judged to be inappropriate as a participant by the principal or collaborating doctors